Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.59 |
| ▸ | HTR2A | P28223 | 3/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.43 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8443421 | 0.78 | HRH1 (0.46) | TAAR1HTR2AHRH1DPP4F2 | |
| SCHEMBL10700271 | 0.78 | HTR2A (0.43) | TAAR1HTR2AHRH1DPP4F2 | |
| SCHEMBL647478 | 0.76 | HTR2A (0.42) | TAAR1HTR2AHRH1DPP4F2 | |
| SCHEMBL149259 | 0.75 | HTR2A (1.00) | TAAR1HTR2ACHRNB2CHRNA4HRH1 | |
| SCHEMBL6401479 | 0.74 | TRPA1 (0.45) | TAAR1HTR2ADPP4CYP2D6TSHR | |
| SCHEMBL13473250 | 0.74 | LMNA (0.58) | TAAR1HTR2AHRH1 | |
| SCHEMBL879168 | 0.74 | LMNA (0.58) | TAAR1HTR2AHRH1 | |
| SCHEMBL4260009 | 0.74 | TAAR1 (0.40) | TAAR1HTR2AHRH1DPP4F2 | |
| SCHEMBL19632871 | 0.74 | TRPA1 (0.45) | TAAR1HTR2ADPP4CYP2D6TSHR | |
| SCHEMBL577036 | 0.74 | LMNA (0.58) | TAAR1HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150291-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| CN-112592382-B | Resin, preparation method thereof and application thereof in preparation of head-tail cyclic peptide | 安徽大学 | 2022-10-04 | — | — | CN | disclosed |
| CN-107722148-A | Solid polyaluminoxane composition, catalyst for olefin polymerization, and method for producing olefin polymer | 三井化学株式会社 | 2018-02-23 | — | — | CN | disclosed |
| CN-107722146-A | Method for producing solid polyaluminoxane composition | 三井化学株式会社 | 2018-02-23 | — | — | CN | disclosed |
| CN-104968668-B | Solid polyaluminoxane composition, catalyst for olefin polymerization, method for producing olefin polymer, and method for producing solid polyaluminoxane composition | 三井化学株式会社 | 2017-11-17 | — | — | CN | disclosed |
| US-9249181-B2 | C-terminal amidation of polypeptides | AMYLIN PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140058070-A1 | C-TERMINAL AMIDATION OF POLYPEPTIDES | AstraZeneca Pharmaceuticala LP (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2012036962-A2 | C-TERMINAL AMIDATION OF POLYPEPTIDES | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-7833331-B2 | Non-toxic corrosion-protection pigments based on cobalt | UNIVERSITY OF DAYTON (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
| US-20040104377-A1 | Non-toxic corrosion-protection pigments based on rare earth elements | UNIVERSITY OF DAYTON | 2004-06-03 | — | — | US | disclosed |
| US-20040016910-A1 | Non-toxic corrosion-protection rinses and seals based on rare earth elements | DAYTON, UNIVERSITY OF | 2004-01-29 | — | — | US | disclosed |
| US-20040011252-A1 | Non-toxic corrosion-protection pigments based on manganese | UNIVERSITY OF DAYTON | 2004-01-22 | — | — | US | disclosed |
| US-20030234063-A1 | Non-toxic corrosion-protection conversion coats based on cobalt | DAYTON, UNIVERSITY OF | 2003-12-25 | — | — | US | disclosed |
| WO-2003060192-A1 | NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060191-A2 | NON-TOXIC CORROSION-PROTECTION CONVERSION COATINGES ABSED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060019-A1 | NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-0053015-A1 | 1-Phenylthio-2-aminopropane derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-06-02 | — | — | EP | disclosed |
| US-4001284-A | PRIMARY AMINES, 2,4-DIPHENOXY-5-SULFAMOYLBENZOIC ACID | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-01-04 | — | — | US | disclosed |
| US-3972890-A | ACID CATALYST | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058070-A1 | C-TERMINAL AMIDATION OF POLYPEPTIDES | IAPP, SELENOI, SCLY | TAAR1 2789/4885HTR2A 4756/4885CHRNB2 3641/4885 |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | CNR2, CNR1, SLC18A2 | TAAR1 160/4885HTR2A 33/4885CHRNB2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.